Cusatuzumab
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) [1].
Product Specifications
CAS Number
[1864871-20-4]
Product Name Alternative
ARGX-110
UNSPSC
12352203
Target
Apoptosis
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/cusatuzumab.html
Purity
98.87
Solubility
H2O
Smiles
[Cusatuzumab]
Molecular Weight
(144.36 kDa)
References & Citations
[1]Riether C, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020; 26 (9) :1459-1467.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1147503-01 0.05 mg (Mammalian-Cell)
Recombinant Aneura mirabilis Cytochrome b6-f complex subunit 5 (petG), partial
Ask
View Details MBS1147503-02 0.1 mg (Mammalian-Cell)
Recombinant Aneura mirabilis Cytochrome b6-f complex subunit 5 (petG), partial
Ask
View Details